Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MIZUHO MEDY, Last Fiscal Year Ordinary Profit Revised Upward by 24%, Dividend Revised Upward by 20 yen
4595 MIZUHO MEDY CO.,LTD. 【J-GAAP】
Guidance Update ReportMIZUHO MEDY CO.,LTD. <4595> [TSE Std] announced a revision to its performance and dividend at noon (12:00) on January 27th. The ordinary profit (non-consolidated) for the fiscal year ending December 2024 has been revised upward 23.9%, from the previous forecast of 4.16 billion yen to 5.16 billion yen (compared to 5.29 billion yen in the previous period), and the declining rate is expected to decrease from 21.2% to 2.4%.
Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (2H) ordinary profit has been revised upward 47.8%, from the previous forecast of 2.08 billion yen to 3.08 billion yen (compared to 3.23 billion yen in the same period of the previous year), and the declining rate is expected to decrease from 35.5% to 4.7%.
In light of the strong performance, the company has increased its planned annual dividend for the last fiscal year from the original plan of 120 yen to 140 yen (compared to 200 yen before the 2-for-1 forward stock split in the previous period).
Kabutan News
Guidance Update
Second Half Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jul - Dec, 2024 Prev | 5,762 | 2,319 | 2,088 | 1,527 | 80.2 | 40 | Aug 9, 2024 | J-GAAP |
Jul - Dec, 2024 New | 6,761 | 3,074 | 3,086 | 2,284 | 119.9 | 60 | Jan 27, 2025 | J-GAAP |
Revision Rate | +17.3% | +32.6% | +47.8% | +49.6% | +49.6% |
Full Year Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2024 Prev | 10,430 | 4,162 | 4,169 | 3,016 | 158.3 | 80 | Feb 9, 2024 | J-GAAP |
Dec, 2024 New | 11,429 | 4,917 | 5,167 | 3,773 | 198.1 | 100 | Jan 27, 2025 | J-GAAP |
Revision Rate | +9.6% | +18.1% | +23.9% | +25.1% | +25.1% |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jul - Dec, 2023 | 6,414 | 3,248 | 3,239 | 2,313 | 121.4 | 70 | Feb 9, 2024 | J-GAAP |
Jul - Dec, 2024 Guidance | 6,761 | 3,074 | 3,086 | 2,284 | 119.9 | 60 | Jan 27, 2025 | J-GAAP |
YoY | +5.4% | -5.4% | -4.7% | -1.3% | -1.2% |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2022 | 17,581 | 11,104 | 11,070 | 7,838 | 411.5 | 125 | Feb 10, 2023 | J-GAAP |
Dec, 2023 | 10,989 | 5,151 | 5,292 | 3,774 | 198.1 | 100 | Feb 9, 2024 | J-GAAP |
Dec, 2024 Guidance | 11,429 | 4,917 | 5,167 | 3,773 | 198.1 | 100 | Jan 27, 2025 | J-GAAP |
YoY | +4.0% | -4.5% | -2.4% | 0.0% | 0.0% |
Related Articles
NIPPON PALLET POOL, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 44%, Oct-Dec Ordinary Profit Decreases by 47%
FUJITSU GENERAL, Oct-Dec (3Q) Net Income Turns to Profit
ATOM LIVIN TECH, First Half Ordinary Profit Revised Upward to an Unexpected 37% Increase
Genky DrugStares, First Half Ordinary Profit Increases by 5%
NAGAWA Co, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 6%
Nikkei 225 open on the 27th = 195 yen higher, 40,127 yen
Nikkei 225 close on the 24th = falling for the first time in 5 days, 26 yen lower to 39,931 yen
Silver Egg Tech, Last Fiscal Year Ordinary Profit Revised Downward to an Unexpected 31% Decrease
NIHON KOGYO, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 59%, Oct-Dec Ordinary Profit Increases by 3.4 times
Astellas Pharma, The Current Fiscal Year Net Income Revised Downward to an Unexpected 18% Decrease